Zobrazeno 1 - 10
of 126
pro vyhledávání: '"PCSK9 (proprotein convertase subtilisin/kexin type 9)"'
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
Recent clinical trials demonstrated that proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors reduce cardiovascular events without affecting systemic inflammation in the patients with coronary artery disease, as determined by high sensitivity
Externí odkaz:
https://doaj.org/article/3e447212c28f4950be5249f5829f0f08
Autor:
Samantha K. Sarkar, Angela Matyas, Ikhuosho Asikhia, Zhenkun Hu, Mia Golder, Kaitlyn Beehler, Tanja Kosenko, Thomas A. Lagace
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds and mediates endo-lysosomal degradation of low-density lipoprotein receptor (LDLR), limiting plasma clearance of cholesterol-rich LDL particles in liver. Gain-of-f
Externí odkaz:
https://doaj.org/article/5b011592ba30443bbae7dc2981011534
Autor:
Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells. We hypothesized that serum PCSK9
Externí odkaz:
https://doaj.org/article/7e3cf716450a433d908da82477555712
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Statins are the first choice for lowering low-density lipoprotein cholesterol (LDL-C) and preventing atherosclerotic cardiovascular disease (ASCVD). However, statins can also upregulate proprotein convertase subtilisin/kexin type 9 (PCSK9), which in
Externí odkaz:
https://doaj.org/article/90d2c85a881d4e6d9b4db812fd190094
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulat
Externí odkaz:
https://doaj.org/article/1343f8ade84c41639a9717d3b3a9a7e8
Autor:
Chiara Macchi, Maria Francesca Greco, Chiara Favero, Laura Dioni, Laura Cantone, Mirjam Hoxha, Luisella Vigna, Giulia Solazzo, Alberto Corsini, Maciej Banach, Angela C. Pesatori, Valentina Bollati, Massimiliano Ruscica
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2022)
Background: Extracellular vesicles (EV) concentration is generally increased in patients with cardiovascular diseases, although the protective role of EVs in atherosclerosis has been reported. Among the specific cargo of EVs, miRNAs contribute to dif
Externí odkaz:
https://doaj.org/article/86f808a5a65942aaaad82e9cc4d8e1e4
Autor:
Paola G. Simeone, Francesco Vadini, Romina Tripaldi, Rossella Liani, Sonia Ciotti, Augusto Di Castelnuovo, Francesco Cipollone, Francesca Santilli
Publikováno v:
Frontiers in Aging Neuroscience, Vol 13 (2021)
Background: Growing evidence indicates that cognitive decline and cardiovascular diseases (CVDs) share common vascular risk factors. Protease proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with CV disease risk and has been also i
Externí odkaz:
https://doaj.org/article/4a6b958d25ae4b9783a757721fac4065
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR
Externí odkaz:
https://doaj.org/article/c9369473dc9b4d779536b80736f8a5f1
Autor:
Arman Moradi, Majid Maleki, Zahra Ghaemmaghami, Zahra Khajali, Feridoun Noohi, Maryam Hosseini Moghadam, Samira Kalyinia, Seyed Javad Mowla, Nabil G. Seidah, Mahshid Malakootian
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Familial hypercholesterolemia (FH) is a common, yet underdiagnosed, genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol levels, which can increase the risk of early-onset coronary artery disease (CAD). In the prese
Externí odkaz:
https://doaj.org/article/21adc885351f4292b14e165bc585572f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.